Diagnosis and treatment of transfusion-related iron overload
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혁 | - |
dc.date.accessioned | 2022-12-10T02:40:08Z | - |
dc.date.available | 2022-12-10T02:40:08Z | - |
dc.date.created | 2022-11-08 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86243 | - |
dc.description.abstract | Background: Iron overload is frequently found in transfused patients with chronic anemia and congenital hemochromatosis. Iron toxicity adversely affects organs, including the heart, liver, and endocrine glands. Iron chelation helps patients with transfusion-related iron overload improve organ dysfunction and prolong survival. Current Concepts: Iron overload is classified into primary and secondary causes. Acquired causes of secondary iron overload include ineffective erythropoiesis, chronic transfusion, and chronic liver diseases. The effectiveness of iron chelation therapy in reducing or maintaining body iron has been demonstrated in many studies of patients with transfusion-induced anemias. Deferasirox, a once-daily oral iron chelator for adult and pediatric patients with transfusion-induced iron overload, is available in Korea. The initial daily dose of deferasirox recommended by Korean guidelines is 20 mg/kg body weight, taken on an empty stomach at least 30 minutes before meals. Serum ferritin levels should be maintained below 1,000 ng/mL. Discussion and Conclusion: Iron chelation therapy should be considered when a patient has undergone large red blood cell transfusions, and there is evidence of organ iron overload to improve organ dysfunction and survival. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한의사협회 | - |
dc.relation.isPartOf | 대한의사협회지 | - |
dc.title | Diagnosis and treatment of transfusion-related iron overload | - |
dc.title.alternative | 수혈성 철과잉증의 진단 및 치료 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000886241300006 | - |
dc.identifier.doi | 10.5124/jkma.2022.65.10.662 | - |
dc.identifier.bibliographicCitation | 대한의사협회지, v.65, no.10, pp.662 - 672 | - |
dc.identifier.kciid | ART002894122 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85143129054 | - |
dc.citation.endPage | 672 | - |
dc.citation.startPage | 662 | - |
dc.citation.title | 대한의사협회지 | - |
dc.citation.volume | 65 | - |
dc.citation.number | 10 | - |
dc.contributor.affiliatedAuthor | 김혁 | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | 수혈 | - |
dc.subject.keywordAuthor | 철과잉 | - |
dc.subject.keywordAuthor | 혈색소증 | - |
dc.subject.keywordAuthor | 철 킬레이트화 | - |
dc.subject.keywordAuthor | Blood transfusion | - |
dc.subject.keywordAuthor | Iron overload | - |
dc.subject.keywordAuthor | Hemochromatosis | - |
dc.subject.keywordAuthor | Iron chelating agents | - |
dc.subject.keywordPlus | BETA-THALASSEMIA MAJOR | - |
dc.subject.keywordPlus | HEPATITIS-C VIRUS | - |
dc.subject.keywordPlus | CHELATION-THERAPY | - |
dc.subject.keywordPlus | SERUM FERRITIN | - |
dc.subject.keywordPlus | PULMONARY-HYPERTENSION | - |
dc.subject.keywordPlus | MAGNETIC-RESONANCE | - |
dc.subject.keywordPlus | YERSINIA-ENTEROCOLITICA | - |
dc.subject.keywordPlus | DEFERASIROX | - |
dc.subject.keywordPlus | DEFERIPRONE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.